Quantitative analysis for Smith & Nephew plc (SNN) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Unrated (50.0). 29 signals analyzed (26 differentiated alt-data).
SNN stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $30.93 | $30.36 | $30.38 |
| 2026-05-11 | $29.75 | $29.08 | $29.10 |
| 2026-05-21 | $30.91 | $30.47 | $30.76 |
| 2026-06-03 | $30.00 | $29.44 | $29.93 |
| 2026-06-15 | $30.79 | $30.35 | $30.46 |
| 2026-06-26 | $30.27 | $29.86 | $30.04 |
| 2026-07-09 | $30.40 | $29.85 | $30.40 |
| 2026-07-21 | $30.21 | $29.84 | $30.21 |
| 2026-07-31 | $31.59 | $31.20 | $31.56 |
| 2026-08-12 | $29.92 | $29.52 | $29.84 |
| 2026-08-24 | $29.74 | $29.40 | $29.62 |
| 2026-09-03 | $29.24 | $28.48 | $28.69 |
How Smith & Nephew plc stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | — |
| ASND | Ascendis Pharma A/S | $14.9B | — |
| RDY | Dr. Reddy's Laboratories Limited | $11.3B | — |
| GMAB | Genmab A/S | $16.7B | — |
View all Health Care stocks by valuation and signals →
Smith & Nephew plc (SNN) scores Unrated (50.0), and the composite conceals a 61-point disagreement between its dimensions. It is strongest on valuation at 78, and weakest on analyst consensus at 36 and technicals at 17. A stock can carry valuation that high while technicals sits at 17; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| valuation | 78 |
| analyst consensus | 36 |
| technicals | 17 |
StoQuant analyzes 29 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Smith & Nephew plc (SNN): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/SNN"><img src="https://stoquant.com/badge/SNN.svg" alt="Smith & Nephew plc (SNN) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.